Saturday, November 7, 2026
  • About Web3Wire
  • Web3Wire NFTs
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Media Network
  • RSS Feed
  • Contact Us
Web3Wire
No Result
View All Result
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
No Result
View All Result
Web3Wire
No Result
View All Result
Home Press Release GlobeNewswire

Neuralisse Introduces Neuralisse Capsules Multi-Ingredient Dietary Supplement Featuring Six Listed Ingredients

October 17, 2026
in GlobeNewswire, Web3
Reading Time: 21 mins read
5
SHARES
249
VIEWS
Share on TwitterShare on LinkedInShare on Facebook

Neu alisse the fo mulatio co tai s a 575 mg p op ieta y ble d featu i g mag esium glyci ate, alpha-lipoic acid, butche ’s b oom oot ext act, L-ca iti e, tu me ic hizome ext act, a d coe zyme Q10.

Ogde , UT, Oct. 16, 2026 (GLOBE NEWSWIRE) — Neu alisse has a ou ced a multi-i g edie t dieta y suppleme t fo mulated with a p op ieta y ble d of six listed i g edie ts. The fo mulatio b i gs togethe a mi e al compou d, seve al ut itio al a d biochemical compou ds, a d bota ical ext acts i a si gle dieta y suppleme t. Acco di g to the p oduct i fo matio p ovided, the p op ieta y ble d has a total listed weight of 575 millig ams.

Official Website Neu alisse

The i g edie t list i cludes mag esium glyci ate, alpha-lipoic acid, butche ’s b oom (Ruscus aculeatus) oot ext act, L-ca iti e, tu me ic (Cu cuma lo ga) hizome ext act sta da dized to 95% cu cumi oids, a d coe zyme Q10 i the fo m of ubiqui o e. These i g edie ts have disti ct chemical cha acte istics a d histo ies of use i ut itio al p oducts a d bota ical p epa atio s.

The a ou ceme t p ovides i fo matio about the fo mulatio a d its listed compo e ts. It does ot establish the effective ess of the fi ished p oduct fo e ve suppo t o a y othe health outcome. I dividual i g edie t esea ch, whe e available, should ot be i te p eted as evide ce that a pa ticula combi atio p oduces the same effects.

A Fo mulatio Combi i g Six I g edie ts

The Neu alisse fo mulatio b i gs togethe six i g edie ts withi o e p op ieta y ble d. The stated ble d weight is 575 mg, ep ese ti g the combi ed amou t athe tha the i dividual qua tity of each compo e t.

A p op ieta y ble d ide tifies a g oup of i g edie ts u de a collective amou t o a p oduct label. Depe di g o the applicable labeli g equi eme ts a d the i fo matio disclosed by the ma ufactu e , i dividual qua tities may ot be p ovided fo eve y compo e t. Co seque tly, the total ble d weight alo e does ot establish the p ecise amou t of mag esium glyci ate, alpha-lipoic acid, o a y othe listed i g edie t.

This disti ctio is eleva t whe eviewi g multi-i g edie t dieta y suppleme ts. I g edie t ide tity, qua tity pe se vi g, se vi g i st uctio s, a d the fo m i which each i g edie t is supplied a e sepa ate pieces of i fo matio . The available p oduct details ide tify the six i g edie ts a d the total ble d weight but do ot p ovide i dividual i g edie t qua tities.

The fo mulatio also illust ates how diffe e t i g edie t catego ies ca appea togethe i a si gle suppleme t. Mag esium glyci ate is a mag esium compou d, alpha-lipoic acid a d L-ca iti e a e biochemical compou ds used i ut itio al p oducts, a d coe zyme Q10 is a compou d fou d atu ally i the body. Butche ’s b oom a d tu me ic a e bota ical i g edie ts.

The p ese ce of these i g edie ts desc ibes the compositio of the p oduct. It does ot, by itself, demo st ate a pa ticula physiological effect o establish that the combi atio has bee evaluated i cli ical studies.

Mag esium Glyci ate

Mag esium glyci ate is a fo m of mag esium associated with the ami o acid glyci e. Mag esium is a esse tial mi e al i volved i ume ous o mal physiological p ocesses, i cludi g muscle fu ctio , e ve sig ali g, a d e e gy metabolism.

The fo m of mag esium used i a suppleme t is o e facto co sume s may e cou te whe compa i g i g edie t labels. Howeve , the i g edie t ame alo e does ot eveal the amou t of eleme tal mag esium supplied by a se vi g. That i fo matio depe ds o the specific i g edie t mate ial a d its fo mulatio .

Fo Neu alisse, mag esium glyci ate is o e of six listed compo e ts i the p op ieta y ble d. The supplied i fo matio does ot specify its i dividual qua tity o the amou t of eleme tal mag esium p ovided pe se vi g. These details would be ecessa y to cha acte ize the p oduct’s mag esium co t ibutio accu ately.

The i clusio of mag esium glyci ate should the efo e be u de stood as a fo mulatio detail athe tha evide ce that the fi ished suppleme t add esses a mag esium deficie cy o p oduces a specific e ve- elated outcome.

Alpha-Lipoic Acid

Alpha-lipoic acid is a compou d i volved i cellula e e gy metabolism. It is also discussed i scie tific lite atu e co ce i g its chemical p ope ties a d a tioxida t activity. Alpha-lipoic acid appea s i va ious ut itio al suppleme t fo mulatio s, although the sig ifica ce of esea ch fi di gs depe ds o the specific applicatio , dosage, populatio , a d study desig .

Resea ch i volvi g a i dividual i g edie t does ot automatically establish the effects of eve y suppleme t co tai i g that i g edie t. Diffe e ces i fo mulatio , qua tity, admi ist atio , a d study co ditio s ca i flue ce whethe fi di gs a e eleva t to a othe p oduct.

I the Neu alisse ble d, alpha-lipoic acid is listed alo gside five othe i g edie ts. The available fo mulatio i fo matio does ot ide tify its i dividual amou t o i dicate whethe the completed p oduct has bee evaluated i a co t olled cli ical study.

Acco di gly, its i clusio ca be epo ted as pa t of the p oduct’s compositio without att ibuti g a specific the apeutic effect to the fi ished suppleme t.

Butche ’s B oom Root Ext act

Butche ’s b oom, scie tifically k ow as Ruscus aculeatus, is a pla t whose oots a d u de g ou d stems have bee used i t aditio al bota ical p epa atio s. Ext acts f om the pla t a e i cluded i some dieta y suppleme ts.

Bota ical i g edie ts ca va y acco di g to the pla t mate ial used, g owi g co ditio s, ext actio methods, a d ma ufactu i g specificatio s. The scie tific ame helps ide tify the pla t, but it does ot i depe de tly establish the co ce t atio of pa ticula co stitue ts o the quality of a fi ished ext act.

Neu alisse lists butche ’s b oom oot ext act as o e of the compo e ts i its 575 mg p op ieta y ble d. The supplied i fo matio does ot ide tify the ext act atio, sta da dizatio details, o i dividual amou t used i the fo mulatio .

These disti ctio s matte whe i te p eti g bota ical suppleme t labels. The ame of a pla t ext act p ovides i fo matio about its sou ce, while additio al specificatio s may be eeded to cha acte ize the ext act mo e fully.

The i g edie t’s p ese ce i the Neu alisse fo mulatio does ot establish that the fi ished p oduct has demo st ated be efits fo e ve health, ci culatio , o a y medical co ditio .

L-Ca iti e

L-ca iti e is a compou d i volved i the t a spo t of lo g-chai fatty acids i to mitocho d ia, whe e they ca be used i cellula e e gy p oductio . The body p oduces L-ca iti e, a d it is also obtai ed th ough dieta y sou ces.

L-ca iti e is used i a a ge of ut itio al p oducts. Scie tific i vestigatio s i volvi g the compou d add ess diffe e t questio s, a d thei fi di gs must be co side ed i the co text of the specific fo mulatio , amou t admi iste ed, study populatio , a d measu ed outcome.

The Neu alisse i g edie t list ide tifies L-ca iti e as o e of the six compo e ts i the p op ieta y ble d. No i dividual qua tity is p ovided i the supplied p oduct i fo matio .

Without that qua tity a d fu the i fo matio about the fi ished fo mulatio , it would be i app op iate to i fe how much L-ca iti e a se vi g p ovides o to p edict a pa ticula outcome f om its i clusio .

Its listi g is the efo e a stateme t about the fo mulatio ‘s compositio , ot a claim that Neu alisse has bee show to imp ove e e gy p oductio , elieve discomfo t, o ma age a health co ditio .

Tu me ic Rhizome Ext act a d Cu cumi oids

Tu me ic, o Cu cuma lo ga, is a pla t commo ly used as a culi a y spice a d i t aditio al p epa atio s. Its hizome co tai s compou ds k ow as cu cumi oids, i cludi g cu cumi . Tu me ic-de ived i g edie ts a e used i foods, bota ical p epa atio s, a d dieta y suppleme ts.

The Neu alisse i g edie t i fo matio ide tifies tu me ic hizome ext act sta da dized to 95% cu cumi oids. This specificatio desc ibes the stated co ce t atio of cu cumi oids i the ext act i g edie t. It does ot mea that 95% of the e ti e 575 mg p op ieta y ble d co sists of cu cumi oids.

Because the i dividual qua tity of tu me ic ext act has ot bee p ovided, the total amou t of cu cumi oids pe se vi g ca ot be calculated f om the ble d weight alo e.

Sta da dizatio is o e of seve al details that ca help cha acte ize a bota ical i g edie t. Othe eleva t i fo matio may i clude the pla t mate ial used, ext actio p ocess, quality specificatio s, a d a alytical methods used to ve ify compositio .

Scie tific i te est i tu me ic a d cu cumi oids cove s a a ge of topics, but evide ce co ce i g a isolated compou d o a diffe e t p epa atio ca ot automatically be applied to eve y tu me ic-co tai i g suppleme t. The fo mulatio details a d available esea ch must be co side ed befo e d awi g co clusio s about a pa ticula p oduct.

Fo Neu alisse, the stated sta da dizatio is a compositio al detail. It is ot p oof of a specific health be efit o evide ce that the completed suppleme t has u de go e cli ical testi g.

Coe zyme Q10 as Ubiqui o e

Coe zyme Q10, commo ly abb eviated as CoQ10, is a compou d fou d atu ally i the body a d i volved i mitocho d ial e e gy p oductio . It also pa ticipates i cellula p ocesses elated to oxidatio a d eductio .

Coe zyme Q10 is available i suppleme t p oducts i diffe e t fo ms. The Neu alisse i g edie t list specifies ubiqui o e, a oxidized fo m of coe zyme Q10. Ide tifyi g the fo m p ovides additio al i fo matio about the i g edie t used i the fo mulatio .

The supplied p oduct details do ot specify the amou t of ubiqui o e co tai ed i a i dividual se vi g. As a esult, the p oduct’s co t ibutio of coe zyme Q10 ca ot be qua tified f om the total p op ieta y-ble d weight.

Resea ch co ce i g coe zyme Q10 va ies i its objectives a d fi di gs. Results f om studies i volvi g diffe e t doses, populatio s, o fo mulatio s should ot be t eated as di ect evide ce of the effects of Neu alisse.

Its i clusio i the ble d ide tifies a othe compo e t of the fo mulatio but does ot establish that the fi ished p oduct p oduces a measu able imp oveme t i e ve fu ctio o a y othe cli ical outcome.

U de sta di g the P op ieta y Ble d

The stated 575 mg p op ieta y ble d is a impo ta t pa t of the p oduct i fo matio because it ide tifies the combi ed qua tity assig ed to the six listed i g edie ts. It should ot be i te p eted as 575 mg of each i g edie t o as the amou t of a y si gle compo e t.

Whe a suppleme t co tai s multiple i g edie ts, the total ble d weight does ot i dicate how that weight is dist ibuted. Without i dividual qua tities, co sume s a d healthca e p ofessio als ca ot dete mi e the p ecise co t ibutio of each listed compo e t f om the i fo matio supplied.

The same disti ctio applies whe i te p eti g i g edie t esea ch. A study exami i g a specific qua tity of o e i g edie t may ot p ovide a mea i gful basis fo evaluati g a p op ieta y ble d whe the amou t of that i g edie t is u k ow .

Othe p oduct i fo matio ca also be eleva t to a complete u de sta di g of a dieta y suppleme t. This may i clude se vi g size, di ectio s fo use, additio al i g edie ts, alle ge i fo matio whe e applicable, ma ufactu i g details, quality-co t ol p actices, a d safety wa i gs.

The available Neu alisse i fo matio establishes the ames of the six i g edie ts a d the total stated ble d weight. It does ot p ovide all of these additio al details, a d o e should be assumed without co fi matio f om the p oduct label o ma ufactu e .

Dieta y Suppleme ts a d Respo sible P oduct I fo matio

Dieta y suppleme ts a e disti ct f om co ve tio al foods a d medici es i thei i te ded uses a d egulato y t eatme t. P oduct labels p ovide i fo matio about i g edie ts, se vi g sizes, di ectio s, a d othe details eleva t to the p oduct’s i te ded use.

Co sume s co side i g a ew suppleme t should ead the complete label a d assess the p oduct i the co text of thei i dividual ci cumsta ces. A list of i g edie ts alo e does ot establish whethe a fo mulatio is app op iate fo a pa ticula pe so .

People who take p esc iptio o o p esc iptio medici es, have existi g medical co ditio s, o a e p eg a t o u si g should co sult a qualified healthca e p ofessio al befo e begi i g a ew dieta y suppleme t. A healthca e p ofessio al ca co side eleva t medical histo y, cu e t medici es, a d othe facto s whe discussi g suppleme t use.

I g edie t-specific safety i fo matio may also be impo ta t. The fact that a i g edie t is de ived f om a pla t o occu s atu ally i the body does ot mea that eve y dose o combi atio is suitable fo eve yo e. Pote tial i te actio s a d p ecautio s ca depe d o the i g edie t, qua tity, a d i dividual ci cumsta ces.

P oduct i fo matio should also disti guish betwee a suppleme t’s compositio a d evide ce of its effects. Stateme ts about the p ese ce of a i g edie t ca be ve ified agai st a app op iate label, while claims about health outcomes equi e eleva t a d eliable suppo ti g evide ce.

Scope of the A ou ceme t

The Neu alisse a ou ceme t co ce s a multi-i g edie t dieta y suppleme t with a stated 575 mg p op ieta y ble d. The six listed i g edie ts a e mag esium glyci ate, alpha-lipoic acid, butche ’s b oom oot ext act, L-ca iti e, tu me ic hizome ext act sta da dized to 95% cu cumi oids, a d coe zyme Q10 i the fo m of ubiqui o e.

The available i fo matio suppo ts a desc iptio of these i g edie ts a d the stated total ble d weight. It does ot establish i dividual i g edie t qua tities, the cli ical effective ess of the fi ished p oduct, o its suitability fo a pa ticula health co ditio .

No co clusio s about t eatme t outcomes, p eve tio of disease, o the ma ageme t of e ve- elated symptoms should be d aw f om the i g edie t list alo e. Such co clusio s would equi e app op iate evide ce specific to the claim a d, whe e eleva t, the fi ished fo mulatio .

The a ou ceme t does ot compa e Neu alisse with othe p oducts o make a a ki g based o quality, effective ess, o co sume p efe e ce. It also does ot ely o custome testimo ials, sea ch t e ds, o u ve ified co sume a alysis as evide ce.

By p ese ti g the available fo mulatio i fo matio i a factual fo mat, this a ou ceme t p ovides a desc iptio of the p oduct’s listed compositio while disti guishi g those details f om questio s that equi e additio al docume tatio o scie tific evaluatio .

About Neu alisse

Neu alisse is the ame associated with the dieta y suppleme t desc ibed i this a ou ceme t. The supplied p oduct i fo matio ide tifies a p op ieta y ble d with a total stated weight of 575 mg a d six listed i g edie ts. Additio al details about the ma ufactu e , p oduct specificatio s, quality assu a ce, dist ibutio , a d i dividual i g edie t qua tities we e ot p ovided fo this a ou ceme t.

CONTACT: Pho e Suppo t: +1 323-403-4725
Email Suppo t: suppo t@ eu alisse.com

About Web3Wire
Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming.
Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.

ShareTweet1ShareSendShare2
Previous Post

Americas Cardroom Pros Head Into Final Weekend of $6.5M Dual Venoms

Next Post

Horse Honey Capsules Introduces Horse Honey Multi-Ingredient Dietary Supplement Featuring Eleven Ingredients

Related Posts

Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2026 and Declares Quarterly Dividend

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Co stellatio Softwa e I c. (TSX:CSU) (“Co stellatio ” o the “Compa y”) today a ou ced its fi a cial esults fo the thi d qua te e ded Septembe 30, 2026 a d decla ed a $1.00 pe sha e...

Read moreDetails

Parker Scheduled to Present at Robert W. Baird Global Industrial Conference on November 10 at 10:50 a.m. Central Time (11:50 a.m. Eastern Time)

CLEVELAND, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Pa ke Ha ifi Co po atio (NYSE: PH), the global leade i motio a d co t ol tech ologies, today a ou ced that it is scheduled to p ese t at the Robe t W. Bai d Global I dust...

Read moreDetails

Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET

HOLMDEL, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BIO-key I te atio al, I c. (NASDAQ: BKYI), a global leade i ide tity a d access ma ageme t a d biomet ic authe ticatio tech ologies, will elease its thi d qua te 2026 esults p ema ket a...

Read moreDetails

Tactfolio Inc. Launches AI-Compatible Platform for Building, Backtesting, and Automating Trading Strategies

The platfo m combi es AI-assisted st ategy c eatio , histo ical ma ket testi g, pape t adi g, a d automated executio th ough Alpaca b oke age accou ts.New Castle, Delawa e, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Tactfolio I c. a ou ces the lau...

Read moreDetails

Crusoe Announces Wyoming Data Center Campus Update

Google acqui ed southeast Wyomi g p oject f om C usoeDENVER, Nov. 06, 2026 (GLOBE NEWSWIRE) -- C usoe, the AI facto y compa y, today a ou ced its site i southeast Wyomi g has bee acqui ed by Google. The t a sactio ma ks the completio...

Read moreDetails

DigitalZen Launches on Android, Bringing Its Hard-to-Disable Blocker to Phones

Al eady available o Wi dows, macOS, Li ux, Ch omeOS, a d as sta dalo e b owse exte sio s, DigitalZe ow expa ds to A d oid, with iOS i developme t. SHERIDAN, WY / ACCESS Newswi e / Novembe 6, 2026 / DigitalZe has eleased its...

Read moreDetails

LECTRA: Continuation of the share buyback program

                                                                         P ess Release                                                                 Co tact: i vesto . elatio s@lect a.com Co ti uatio of the sha e buyback p og am Pa is, Novembe 6, 2026, As pa t of its sha e buyback p og am lau ched o May 5, 2026, a d...

Read moreDetails

October Small Business Subchapter V Elections Increase 24% Year Over Year

Total Ba k uptcy Fili gs I c eased 2%NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- The 280 Subchapte V electio s withi Chapte 11 filed du i g Octobe 2026 i c eased 24% f om the 225 fili gs i Octobe 2025, acco di g to data...

Read moreDetails

UPDATE – RJ Lee Group and Carahsoft Partner to Bring Post-Quantum Data Protection and Phishing-Resistant Authentication Solutions to the Public Sector

Powe ful Qua tum-Resilie t Cybe secu ity Solutio s Now Available to Gove me t Age ciesMONROEVILLE, Pa. a d RESTON, Va., Nov. 06, 2026 (GLOBE NEWSWIRE) -- RJ Lee G oup, a scie tific a d tech ical fi m delive i g qua tum- esilie t cybe...

Read moreDetails

LECTRA: Monthly declaration of the total number of shares and voting rights composing the company’s capital (at October 31st, 2026)

Mo thly decla atio of the total umbe of sha es a d voti g ights composi g the compa y's capital (at Octobe 31st, 2026) This decla atio is established i acco da ce with A ticle L.233-8 II of the F e ch Code de Comme ce a...

Read moreDetails
Web3Wire NFTs - The Web3 Collective

Web3Wire, $W3W Token and .w3w tld Whitepaper

Web3Wire, $W3W Token and .w3w tld Whitepaper

Claim your space in Web3 with .w3w Domain!

Web3Wire

Trending on Web3Wire

  • Top Cross-Chain DeFi Solutions to Watch by 2025

    189 shares
    Share 76 Tweet 47
  • Understanding Soulbound Tokens SBT Their Definition and Significance

    85 shares
    Share 34 Tweet 21
  • Discover the Best Metaverse Crypto Projects and Virtual Worlds 2025

    66 shares
    Share 26 Tweet 17
  • Top Layer 1 Crypto Projects to Watch in 2025

    38 shares
    Share 15 Tweet 10
  • Discover 2025’s Top 5 Promising Low-Cap Crypto Gems

    111 shares
    Share 44 Tweet 28
Join our Web3Wire Community!

Our newsletters are only twice a month, reaching around 10000+ Blockchain Companies, 800 Web3 VCs, 600 Blockchain Journalists and Media Houses.


* We wont pass your details on to anyone else and we hate spam as much as you do. By clicking the signup button you agree to our Terms of Use and Privacy Policy.

Web3Wire Podcasts

Upcoming Events

There are currently no events.

Latest on Web3Wire

  • CORRECTION: Vertical Data Closes $4.24 Million Private Placement of Common Stock
  • Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2026 and Declares Quarterly Dividend
  • Parker Scheduled to Present at Robert W. Baird Global Industrial Conference on November 10 at 10:50 a.m. Central Time (11:50 a.m. Eastern Time)
  • Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET
  • Tactfolio Inc. Launches AI-Compatible Platform for Building, Backtesting, and Automating Trading Strategies

RSS feed: Latest on Block3Wire Latest on Block3Wire

  • The Algorithmic Monographs: A Five-Volume Civil Code for the Age of Autonomous Intelligence
  • Ali Sadhik Shaik: Practitioner, Scholar, and Author – Focused on the Governance of Intelligent Systems
  • The Klyrox Protocol: A Decentralized Framework to Close the AI Accountability Gap
  • Covo Finance: Revolutionary Crypto Leverage Trading Platform
  • WorldStrides and HEX Announce Partnership to Offer High School and University Students Innovative Courses Designed to Improve Their Outlook in the Digital Age

RSS feed: Latest on Meta3Wire Latest on Meta3Wire

  • The Algorithmic Monographs: A Five-Volume Civil Code for the Age of Autonomous Intelligence
  • Ali Sadhik Shaik: Practitioner, Scholar, and Author – Focused on the Governance of Intelligent Systems
  • The Klyrox Protocol: A Decentralized Framework to Close the AI Accountability Gap
  • Thumbtack Honored as a 2023 Transform Awards Winner
  • Accenture Invests in Looking Glass to Accelerate Shift from 2D to 3D
Web3Wire

Web3Wire is your go-to source for the latest insights and updates in Web3, Metaverse, Blockchain, AI, Cryptocurrencies, DeFi, NFTs, and Gaming. We provide comprehensive coverage through news, press releases, event updates, and research articles, keeping you informed about the rapidly evolving digital world.

  • About Web3Wire
  • Founder’s Note
  • Web3Wire NFTs – The Web3 Collective
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Event Partners
  • Community Partners
  • Our Media Network
  • Media Kit
  • RSS Feeds
  • Contact Us

Crypto Coins

  • Top 10 Coins
  • Top 50 Coins
  • Top 100 Coins
  • All Coins – Marketcap
  • Crypto Coins Heatmap

Crypto Exchanges

  • Top 10 Exchanges
  • Top 50 Exchanges
  • Top 100 Exchanges
  • All Crypto Exchanges

Crypto Stocks

  • Blockchain Stocks
  • NFT Stocks
  • Metaverse Stocks
  • Artificial Intelligence Stocks

Web3Wire Whitepaper | Tokenomics

Web3 Resources

  • Top Web3 and Crypto Youtube Channels
  • Latest Crypto News
  • Latest DeFi News
  • Latest Web3 News

Blockchain Resources

  • Blockchain and Web3 Resources
  • Decentralized Finance (DeFi) – Research Reports
  • All Crypto Whitepapers

Metaverse Resources

  • AR VR and Metaverse Resources
  • Metaverse Courses
Claim your space in Web3 with .w3w!

The Klyrox Protocol | The Algorithmic Monographs

Top 50 Web3 Blogs and Websites
Web3Wire Podcast on Spotify Web3Wire Podcast on Amazon Music 
Web3Wire - Web3 and Blockchain - News, Events and Press Releases | Product Hunt
Web3Wire on Google News

Media Portfolio: Block3Wire | Meta3Wire

  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • For Search Engines
  • Crypto Sitemap
  • Exchanges Sitemap

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Coins
    • Top 10 Cryptocurrencies
    • Top 50 Cryptocurrencies
    • Top 100 Cryptocurrencies
    • All Coins
  • Exchanges
    • Top 10 Cryptocurrency Exchanges
    • Top 50 Cryptocurrency Exchanges
    • Top 100 Cryptocurrency Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.